  More than 198 million cases of severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) has been reported that result in no fewer than 4.2 million
deaths globally. The rapid spread of the disease coupled with the lack of
specific registered drugs for its treatment pose a great challenge that
necessitate the development of therapeutic agents from a variety of sources. In
this study, we employed an in-silico method to screen natural compounds with a
view to identify inhibitors of the human transmembrane protease serine type 2
(TMPRSS2). The activity of this enzyme is essential for viral access into the
host cells via angiotensin-converting enzyme 2 (ACE-2). Inhibiting the activity
of this enzyme is therefore highly crucial for preventing viral fusion with
ACE-2 thus shielding SARS-CoV-2 infectivity. 3D model of TMPRSS2 was
constructed using I-TASSER, refined by GalaxyRefine, validated by Ramachandran
plot server and overall model quality was checked by ProSA. 95 natural
compounds from microalgae were virtually screened against the modeled protein
that led to the identification 17 best leads capable of binding to TMPRSS2 with
a good binding score comparable, greater or a bit lower than that of the
standard inhibitor (camostat). Physicochemical properties, ADME (absorption,
distribution, metabolism, excretion) and toxicity analysis revealed top 4
compounds including the reference drug with good pharmacokinetic and
pharmacodynamic profiles. These compounds bind to the same pocket of the
protein with a binding energy of -7.8 kcal/mol, -7.6 kcal/mol, -7.4 kcal/mol
and -7.4 kcal/mol each for camostat, apigenin, catechin and epicatechin
respectively. This study shed light on the potential of microalgal compounds
against SARS-CoV-2. In vivo and invitro studies are required to developed
SARS-CoV-2 drugs based on the structures of the compounds identified in this
study.
